Response of DA-Epoch-R in High Grade B-Cell Lymphoma
DOI:
https://doi.org/10.70749/ijbr.v3i2.2724Keywords:
vincristine, cyclophosphamide, doxorubicin and rituximab, dose-adjusted etoposide, B cell lymphoma, and responseAbstract
Introduction: The dosages of chemo immunotherapy medications (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab) are modified based on the toxicity of the preceding cycle. Etoposide, doxorubicin, and cyclophosphamide are subject to dosage adjustments above starting dose level 1, while cyclophosphamide is subject to dose adjustments below starting dose level 1. Materials and Procedures: There were 65 high-grade B cell lymphoma patients in all, both male and female, aged >18–50 years. Patients with hepatitis B, primary CNS lymphoma, and those who had already received treatment were not included. Following their enrollment in the study, these patients received four cycles of DA-EPOCH-R along with 12.5 mg of intrathecal methotrexate. These were monitored prospectively, and following four cycles, the interim response was evaluated using the Deauville criteria based on whole body FDG PET-CT scans. Findings: Participants in this study ranged in age from over 18 to 50, with a mean age of 33.46 ± 7.41 years. 42 patients, or 64.62% of the total, were between the ages of 18 and 50. With a male to female ratio of 2.4:1, 46 (70.77%) of the 65 patients were men and 19 (29.23%) were women. 50 (76.92%) of the patients in my study had a complete response, 14 (21.54%) had a partial response, 01 (1.54%) had stable disease, and 00 (0.0%) had progressing disease. Conclusion: This investigation came to the conclusion that DA-EPOCH-R had a very effective response in high grade B-cell lymphoma.
Downloads
References
High-Grade B-Cell Lymphoma - Lymphoma Research Foundation.”
https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/hgbcl
2. Ott G. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. Br J Haematol. 2017;178(6):871–87.
https://doi.org/10.1111/bjh.14744
3. Items R, Rose W, Rose W, If T, Rose W. Prognostic Signi fi cance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium,” 2019.
4. Wilson WH. A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma Conception and design. Lancet Haematol. 2018;5(12):609–17.
5. McMillan AK. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31(9):1251–59.
https://doi.org/10.1016/j.annonc.2020.05.016
6. Leppä S. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4(9):1906–15.
https://doi.org/10.1182/bloodadvances.2020001518
7. Laude MC. First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. Am J Hematol. 2021;96(3):302–11.
https://doi.org/10.1002/ajh.26068
8. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology (Am Soc Hematol Educ Program). 2016;2016(1):366–378.
https://doi.org/10.1182/asheducation-2016.1.366
9. Wilson WH, Grossbard ML, Pittaluga S. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693.
https://doi.org/10.1182/blood.v99.8.2685
10. Purroy N, Bergua J, Gallur L. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2015;169(2):188–198.
https://doi.org/10.1111/bjh.13273
11. Bartlett NL, Wilson WH, Jung SH. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
https://doi.org/10.1200/jco.18.01994
12. Petrich AM, Gandhi M, Jovanovic B. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
https://doi.org/10.1182/blood-2014-05-578963
13. Howlett C, Snedecor SJ, Landsburg DJ. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–514.
https://doi.org/10.1111/bjh.13463
14. Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A et al. Dose-adjusted Epoch and rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica 2020; 107: 1153–62.
https://doi.org/10.3324/haematol.2021.278638
15. Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia 2019; 33: 1047–51.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
